UY27067A1 - Pirrolo (2.-a) dihidroisoquinolinas - Google Patents

Pirrolo (2.-a) dihidroisoquinolinas

Info

Publication number
UY27067A1
UY27067A1 UY27067A UY27067A UY27067A1 UY 27067 A1 UY27067 A1 UY 27067A1 UY 27067 A UY27067 A UY 27067A UY 27067 A UY27067 A UY 27067A UY 27067 A1 UY27067 A1 UY 27067A1
Authority
UY
Uruguay
Prior art keywords
dihydroisoquinolins
pirrolo
dihydroisoquinolines
phosphodiesterase
pyrrolo
Prior art date
Application number
UY27067A
Other languages
English (en)
Spanish (es)
Inventor
Olaf Weber
Paul Naab
Ulrich Niewoehner
Marcus Bauser
Jens-Kerim Ergueden
Dietmar Flubacher
Thorsten-Oliver Repp
Juergen Stoltefuss
Nils Burkhardt
Andrea Sewing
Karl-Heinz Schlemmer
Michael Schauer
Stephen J Boyer
Mark Miglarese
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY27067A1 publication Critical patent/UY27067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY27067A 2000-12-13 2001-12-12 Pirrolo (2.-a) dihidroisoquinolinas UY27067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25520600P 2000-12-13 2000-12-13
US31031201P 2001-08-06 2001-08-06

Publications (1)

Publication Number Publication Date
UY27067A1 true UY27067A1 (es) 2002-07-31

Family

ID=26944520

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27067A UY27067A1 (es) 2000-12-13 2001-12-12 Pirrolo (2.-a) dihidroisoquinolinas

Country Status (10)

Country Link
US (1) US6930114B2 (enExample)
EP (1) EP1347973A1 (enExample)
JP (1) JP2004517843A (enExample)
AU (1) AU2002227985A1 (enExample)
CA (1) CA2431326A1 (enExample)
HN (1) HN2001000277A (enExample)
PE (1) PE20021085A1 (enExample)
SV (1) SV2002000761A (enExample)
UY (1) UY27067A1 (enExample)
WO (1) WO2002048144A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014116A1 (en) * 2001-08-06 2003-02-20 Bayer Corporation Pyrrolo[2.1-a]isoquinoline derivatives
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
WO2003051877A1 (en) * 2001-12-18 2003-06-26 Bayer Corporation 2-substituted pyrrolo[2.1-a]isoquinolines against cancer
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
EP1578424A4 (en) * 2002-12-12 2007-08-08 Cytovia Inc SUBSTITUTED 1-BENZOYL-3-CYANOPYRROLO1,2-A | CHINOLINES AND THEIR ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS
WO2005002579A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
WO2005003129A1 (en) * 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines as pde10 inhibitors
WO2006075012A2 (en) * 2005-01-12 2006-07-20 Nycomed Gmbh Pyrrolodihydroisoquinolines as antiproliferative agents
WO2006089815A1 (en) * 2005-01-12 2006-08-31 Nycomed Gmbh Novel pyrrolodihydroisoquinolines as pde10 inhibitors
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008001182A1 (en) * 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200944523A (en) * 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011067145A1 (en) 2009-12-04 2011-06-09 Nerviano Medical Sciences S.R.L. Tricyclopyrazole derivatives
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE690792A (enExample) * 1966-12-07 1967-05-16
FR7348M (enExample) * 1967-12-07 1969-10-13
US4719216A (en) * 1983-06-23 1988-01-12 Mcneilab, Inc. Hexahydropyrrolo(2,1-A)isoquinoline derivatives as antidepressants
DE3401018A1 (de) * 1984-01-13 1985-07-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen
GB8718980D0 (en) * 1987-08-11 1987-09-16 May & Baker Ltd Compositions of matter
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
HN2001000277A (es) 2002-01-30
CA2431326A1 (en) 2002-06-20
PE20021085A1 (es) 2003-05-16
SV2002000761A (es) 2002-12-02
WO2002048144A1 (en) 2002-06-20
EP1347973A1 (en) 2003-10-01
US20040138249A1 (en) 2004-07-15
AU2002227985A1 (en) 2002-06-24
US6930114B2 (en) 2005-08-16
JP2004517843A (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
UY27067A1 (es) Pirrolo (2.-a) dihidroisoquinolinas
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
DE69925133D1 (de) Pyrrolobenzodiazepine
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
BR0312116A (pt) Artigo
EE200100235A (et) cGMP PDE-5 inhibiitorit sisaldavad kontrollitud vabanemisega farmatseutilised formulatsioonid
AU2002357137A8 (en) (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
NO20014303L (no) JAK-3-inhibitorer for behandling av allergiske lidelser
ECSP024382A (es) Inhibidores de proteasa de serina
MXPA04006275A (es) Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina.
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
BG105967A (en) C(7) ester substituted taxanes and their use as antitumor agents
MXPA03006420A (es) Diaminotiazoles.
DK1165558T3 (da) Pyrimido[6,1-a]isoquinolin-4-on-derivater
MX2007012567A (es) Combinacion para terapia en hiperplasia benigna de prostata.
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BR0210101A (pt) Combinações antineoplásticas
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
CY1108773T1 (el) 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
DE60127131D1 (de) Tricyclische imidazopyridine
ATE363511T1 (de) Trennfilme
BG100248A (bg) Инхибитори на скваленсинтетаза
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141105